about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

What lat­est wave of lay­offs means for biotech; Ra­dio­ther­a­py short­age; De­liv­er­ing on mR­NA's promis­es; and more

3 years ago
Weekly

FDA re­jects Covid-19 drug over un­cer­tain­ties around small tri­al

3 years ago
FDA+
Coronavirus

Roche, Ex­elix­is' Tecen­triq/Cabome­tyx com­bo flunks sec­ond PhI­II

3 years ago
R&D

Tech, com­merce-fo­cused in­vestor un­veils $500M bet on health­care

3 years ago
Financing

Scoop: As­cle­tis' NASH sub­sidiary scraps US PhII tri­al in fa­vor of Chi­na

3 years ago
R&D
China

No­vo Nordisk of­floads pre­clin­i­cal can­cer can­di­date from $1.1B For­ma buy­out

3 years ago
Deals

Ready to turn a new page, Lan­dos Bio­phar­ma of­floads for­mer lead pro­gram to founder

3 years ago
Deals
R&D

Sarep­ta won't need FDA ad­comm, boost­ing Duchenne gene ther­a­py's odds

3 years ago
Cell/Gene Tx
FDA+

Com­pa­nies flail amid broad biotech fall­out; Sick­le cell reck­on­ing; Fol­low-up on Pfiz­er's CRO trou­ble; and more

3 years ago
Weekly

No­var­tis re­treat from NASH takes down $80M al­liance with Pli­ant Ther­a­peu­tics

3 years ago
R&D

Nek­tar’s lat­est PhII flop threat­ens to un­rav­el $400M-plus deal with Eli Lil­ly

3 years ago
Deals
R&D

Adding to Claudin18.2 port­fo­lio, As­traZeneca pays $63M cash for an­ti­body-drug con­ju­gate out of Chi­na

3 years ago
Deals

Graphite Bio gives up on lead sick­le cell pro­gram, halves staff in wake of safe­ty scare

3 years ago
People
R&D

Vivek Ra­maswamy launch­es bid for US pres­i­den­cy, re­signs from Roivant board

3 years ago
People

Kin­nate en­gi­neers $24M deal to win con­trol of Chi­na joint ven­ture back from Or­biMed, Fore­site

3 years ago
Deals
China

Tan­gled in bank­rupt­cy pro­ceed­ings and le­gal tus­sle, Sor­ren­to se­cures $75M to stay afloat

3 years ago
Financing

En route to BLA fil­ing, Ac­tini­um de­tails PhI­II win for tar­get­ed ra­dio­ther­a­py in acute myeloid leukemia

3 years ago
R&D

Lat­est news on two FDA ap­provals; High-pro­file moves for John Reed, Brent Saun­ders, Christi Shaw..; and more

3 years ago
Weekly

Mod­er­na boasts 'step for­ward' with PhI­II da­ta on flu vac­cine, but an­a­lysts are not so sure

3 years ago
R&D

Up­dat­ed: Pfiz­er drops half of par­tic­i­pants from Ly­me tri­al af­ter say­ing re­search con­trac­tor broke rules

3 years ago
R&D
Pharma

Putting a twist on tar­get­ed ther­a­py, Vor Bio­phar­ma her­alds proof of con­cept for its gene-edit­ed stem cells

3 years ago
R&D
Cell/Gene Tx

Biotech con­sol­i­da­tion con­tin­ues as Nas­daq-list­ed Ery­tech merges with phage ther­a­py de­vel­op­er

3 years ago
Deals

Brent Saun­ders to lead Bausch + Lomb in re­turn to CEO slot

3 years ago
People
Pharma

Work­ing its way through a CRL on lead drug, Su­per­nus taps $150M loan

3 years ago
Financing
First page Previous page 15161718192021 Next page Last page
A service from the Financial Times